Loading
Marizyme, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lichti Braeden, was filed 07 Sept 2023.
Marizyme, Inc.: what insiders have been doing
Marizyme, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Marizyme, Inc. in twelve months, the latest record being from 28 December 2023.
Looking back to 2023, when coverage begins, insiders filed 3 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
5
Thresholds
n/a
Buy Volume
€33,651
3 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -76.2%Entry US$0.18 · Close at T+365 US$0.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$645.8k
Gross profitUS$457.7k71% margin
EBITDA-US$55.4M-8585% margin
Net income-US$69.5M-10767.8% margin
Valuation
Beta0.70
Balance sheet & cash
Total debtUS$20.8M
Free Cash Flow-US$4.7M
Profitability & ownership
ROA-26.6%
% insiders35.0%
% institutions0.0%
Last declaration on 28 December 2023
Declarations5 total
3,815,294 shares@ €0.0914100.0% of flowCommon stockSEC:0001213900-23-099381:0
97,000 shares@ US$0.10Common sharesSEC:0001786112-23-000002:1
Canonical exit: 5 Oct 2023 (T+90)
105,000 shares@ US$0.165Common sharesSEC:0001786112-23-000002:2
Canonical exit: 27 Nov 2023 (T+90)
106,327 shares@ US$0.09100.0% of flowCommon sharesSEC:0001786112-23-000002:0
Canonical exit: 27 Sept 2023 (T+90)
1,063,938 shares@ €0.0905100.0% of flowCommon StockSEC:0001493152-23-013066:0
5 of 5 declarations
About Marizyme, Inc.
Marizyme, Inc. is a NASDAQ-listed company focused on developing therapeutic solutions for serious diseases. It employs innovative technologies to enhance patient outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
